Amedisys Accounts Payable vs Total Permanent Equity Analysis
AMED Stock | USD 90.16 0.16 0.18% |
Amedisys financial indicator trend analysis is way more than just evaluating Amedisys prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amedisys is a good investment. Please check the relationship between Amedisys Accounts Payable and its Total Permanent Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.
Accounts Payable vs Total Permanent Equity
Accounts Payable vs Total Permanent Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amedisys Accounts Payable account and Total Permanent Equity. At this time, the significance of the direction appears to have no relationship.
The correlation between Amedisys' Accounts Payable and Total Permanent Equity is 0.07. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Permanent Equity in the same time period over historical financial statements of Amedisys, assuming nothing else is changed. The correlation between historical values of Amedisys' Accounts Payable and Total Permanent Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Amedisys are associated (or correlated) with its Total Permanent Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Permanent Equity has no effect on the direction of Accounts Payable i.e., Amedisys' Accounts Payable and Total Permanent Equity go up and down completely randomly.
Correlation Coefficient | 0.07 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Accounts Payable
An accounting item on the balance sheet that represents Amedisys obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Amedisys are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Total Permanent Equity
Most indicators from Amedisys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amedisys current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.At present, Amedisys' Enterprise Value Over EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 23.95, whereas Tax Provision is forecasted to decline to about 42.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 980.8M | 962.8M | 457.1M | 447.4M | Total Revenue | 2.2B | 2.2B | 2.2B | 2.3B |
Amedisys fundamental ratios Correlations
Click cells to compare fundamentals
Amedisys Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Amedisys fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.3B | 1.6B | 1.9B | 2.0B | 2.1B | 2.2B | |
Short Long Term Debt Total | 326.1M | 307.0M | 545.6M | 537.9M | 487.2M | 511.6M | |
Other Current Liab | (3.1M) | 373.1M | 291.8M | 229.3M | 356.6M | 374.4M | |
Total Current Liabilities | 326.9M | 456.3M | 374.3M | 355.5M | 473.7M | 497.4M | |
Total Stockholder Equity | 640.5M | 809.2M | 931.4M | 1.1B | 1.1B | 1.1B | |
Property Plant And Equipment Net | 112.9M | 117.2M | 119.7M | 118.9M | 130.8M | 76.0M | |
Net Debt | 295.8M | 225.2M | 502.9M | 497.4M | 360.8M | 378.8M | |
Retained Earnings | 246.4M | 430.0M | 639.1M | 757.7M | 747.9M | 785.3M | |
Accounts Payable | 31.3M | 42.7M | 38.2M | 43.7M | 28.2M | 19.0M | |
Cash | 30.3M | 81.8M | 42.7M | 40.5M | 126.5M | 132.8M | |
Non Current Assets Total | 912.2M | 1.2B | 1.5B | 1.6B | 1.6B | 1.6B | |
Non Currrent Assets Other | 18.9M | 19M | 19.9M | (20.4B) | 19.0M | 19.9M | |
Cash And Short Term Investments | 30.3M | 81.8M | 42.7M | 40.5M | 126.5M | 132.8M | |
Net Receivables | 237.6M | 255.1M | 275.0M | 296.8M | 313.4M | 329.0M | |
Common Stock Shares Outstanding | 33.0M | 33.3M | 33.0M | 32.7M | 32.6M | 23.4M | |
Liabilities And Stockholders Equity | 1.3B | 1.6B | 1.9B | 2.0B | 2.1B | 2.2B | |
Non Current Liabilities Total | 294.3M | 300.1M | 506.4M | 514.1M | 466.7M | 490.0M | |
Inventory | 74.4M | 11.8M | 13.4M | 25.2M | 29.0M | 30.5M | |
Other Current Assets | 8.2M | 25.0M | 39.0M | 51.6M | 57.1M | 60.0M | |
Other Stockholder Equity | 394.0M | 379.2M | 292.3M | 293.9M | 318.6M | 264.1M | |
Total Liab | 621.2M | 756.5M | 880.6M | 869.7M | 940.4M | 987.4M | |
Property Plant And Equipment Gross | 28.1M | 117.2M | 216.6M | 220.2M | 368.6M | 350.2M | |
Total Current Assets | 350.6M | 362.0M | 356.7M | 389.0M | 496.9M | 521.8M | |
Short Term Debt | 37.7M | 40.5M | 44.2M | 82.5M | 88.9M | 93.3M | |
Current Deferred Revenue | 261.1M | 60M | 295.2M | 20.4B | 106.9M | 101.5M | |
Other Liab | 5.9M | 33.6M | 5.0M | 25.2M | 29.0M | 30.5M | |
Other Assets | 12K | 174.6M | 73.3M | 39.3M | 45.2M | 47.5M | |
Long Term Debt | 232.3M | 204.5M | 432.1M | 419.4M | 361.9M | 380.0M | |
Treasury Stock | (251.2M) | (319.1M) | (435.9M) | (461.2M) | (415.1M) | (394.3M) | |
Property Plant Equipment | 28.1M | 23.7M | 119.7M | 16.0M | 18.4M | 17.5M | |
Good Will | 658.5M | 932.7M | 1.2B | 1.3B | 1.2B | 1.3B | |
Intangible Assets | 64.7M | 74.2M | 111.2M | 101.2M | 102.7M | 64.1M | |
Net Tangible Assets | (82.8M) | (197.6M) | (375.9M) | (337.0M) | (303.3M) | (288.1M) | |
Noncontrolling Interest In Consolidated Entity | 1.1M | 1.5M | 45.0M | 55M | 63.3M | 66.4M | |
Retained Earnings Total Equity | 246.4M | 430.0M | 639.1M | 757.7M | 871.3M | 914.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.35) | Earnings Share 2.52 | Revenue Per Share 71.004 | Quarterly Revenue Growth 0.057 | Return On Assets 0.0627 |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.